Related Experiment Videos
Sensitive RIA for the specific determination of insulin lispro
R R Bowsher1, R A Lynch, P Brown-Augsburger
1Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN 46285, USA. bowsher_ronald_r@lilly.com
Clinical Chemistry
|January 23, 1999
Summary
A new assay can now specifically measure insulin lispro, an insulin analog, even when natural insulin is present. This breakthrough allows for more precise monitoring of insulin lispro levels in patients.
Area of Science:
- Biochemistry
- Immunology
- Endocrinology
Background:
- Insulin lispro, an altered insulin analog, shares high homology with endogenous insulin, hindering specific measurement.
- Accurate quantification of insulin lispro offers clinical advantages over total immunoreactive insulin measurements.
Purpose of the Study:
- To develop a specific and sensitive assay for quantifying insulin lispro in serum.
- To overcome the challenge of distinguishing insulin lispro from endogenous insulin.
Main Methods:
- Development of a novel immunoadsorption strategy using despentapeptide insulin to create a monospecific antiserum.
- Utilization of the specific antiserum in a competitive radioimmunoassay (RIA) for insulin lispro.
Main Results:
- The developed RIA demonstrated a low limit of quantification (17.2 pmol/L).
- The assay showed no interference from insulin, proinsulin, or C-peptide.
- High precision was observed with interassay coefficients of variation (CVs) ranging from 2.6% to 13.4%.
Conclusions:
- A novel competitive RIA has been successfully developed for the specific determination of insulin lispro.
- This assay is suitable for measuring serum insulin lispro concentrations, offering improved specificity compared to existing methods.